T-2307, a broad-spectrum arylamidine compound, demonstrates potent antifungal properties both in vitro and in vivo. Its activity extends to clinically significant pathogens such as Candida species (MIC range: 0.00025 to 0.0078 μg/ml), Cryptococcus neoformans (MIC range: 0.0039 to 0.0625 μg/ml), and Aspergillus species (MIC range: 0.0156 to 4 μg/mL).

T-2307 demonstrates strong efficacy against both fluconazole-resistant and fluconazole-susceptible-dose-dependent strains of Candida albicans, as well as azole-susceptible strains[1]. Additionally, T-2307 is effective in a murine model of Candida glabrata infection, showing positive results despite in vitro trailing growth phenomena[2]. In a Cell Viability Assay[2] using the C. glabrata ATCC 90030 cell line, concentrations ranging from 0.000125 to 0.125 μg/mL were tested over 24 and 48 hours. Significant trailing growth was observed at concentrations from 0.0039 to 0.125 μg/mL at the 48-hour mark, with similar growth patterns noted at 24 hours, indicating T-2307's potential against C. glabrata infections despite initial growth resistance.

In studies using 4-week-old specific-pathogen-free ICR strain male mice with systemic infections of Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus, T-2307 demonstrated efficacy at notably low doses. The effective dose to reduce mortality by 50% (ED50) for disseminated candidiasis, cryptococcosis, and aspergillosis were found to be 0.00755 mg/kg, 0.117 mg/kg, and 0.391 mg/kg, respectively. Mice were administered T-2307 subcutaneously at dosages of 0.001, 0.1, and 1 mg/kg once daily for a week, starting two hours post-infection. Results indicated significant improvements in survival; for Candida albicans infections, Control mice succumbed by day 6, while a delay in mortality was observed with a 0.01 mg/kg dose of T-2307. Similarly, for Cryptococcus neoformans infections, control mice perished by day 9, but those treated with 0.1 mg/kg of T-2307 showed a marked mortality delay. In the case of Aspergillus fumigatus infections, treatment with 1 mg/kg of T-2307 significantly delayed mortality compared to control mice, which all died by day 6. These findings highlight T-2307's potent antifungal activity across different fungal infections at minimal effective dosages.